Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 25 July 2013 | By Louise Zornoza,
The UK's National Institute for Health and Care Excellence (NICE) issued final guidance on 24 July 2013 recommending reimbursement for Bayer's Eylea (aflibercept solution for injection) as an option for treating wet age-related macular degeneration (AMD) only if it is used in accordance with the recommendations for ranibizumab.
Clinical commissioning groups in England, the National Health Service (NHS) England and local authorities must comply with the NICE recommendations within three months of the date of publication.
There are an estimated 26,000 new cases of wet AMD in the UK each year. Risk factors include increasing age, cigarette smoking (smokers having a 3.6 times greater risk of developing age-related macular degeneration compared with people who have never smoked), and exposure to high levels of UV light. It is also more common in women than men.
NICE Guidance on Eylea
Read all Breaking News from RegLink
Tags: Final Guidance, Bayer, UK, guidance, EU